ritlecitinib
oral, dual JAK3/TEC kinase inhibitor Ph. III for alopecia areata structure-based design from tofacitinib The Lancet, May 6, 2023 Pfizer, Groton, CT
Molecules of the Month - May 2023
oral, dual JAK3/TEC kinase inhibitor Ph. III for alopecia areata structure-based design from tofacitinib The Lancet, May 6, 2023 Pfizer, Groton, CT
Molecules of the Month - May 2023